PD-1/PD-L1阻害薬のパイプライン分析

P&S Market Researchが発行した調査報告書(PSM802086)
◆英語タイトル:Global Programmed Death-1 (PD-1) & Programmed Death Ligand-1 (PD-L1) Inhibitors Pipeline Analysis, Market Size, Share, Development, Growth and Demand Forecast to 2025 - Industry Insights by Drug (Opdivo, Keytruda, Tecentriq, Durvalumab, Avelumab), by Mechanism of Action (PD-1 Inhibitor, PD-L1 Inhibitor)
◆商品コード:PSM802086
◆発行会社(リサーチ会社):P&S Market Research
◆発行日:2017年1月1日
◆ページ数:168
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD6,500 ⇒換算¥734,500見積依頼/購入/質問フォーム
Group License(5名様閲覧用)USD7,500 ⇒換算¥847,500見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD10,500 ⇒換算¥1,186,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はP&S Market Research社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。P&S Market Research社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

The global programmed death-1 (PD-1) and programmed death ligand-1 (PD-L1) inhibitors market is valued at an estimated $4,926.4 million in 2016, and it is expected to grow at a CAGR of 23.4% during 2017 – 2025. The growth of the global market is largely driven by the increased investment and funding, strong pipeline, and improved safety and efficacy.
Some of the other factors driving the growth of the global market include technological advancements and innovations, and high prevalence of cancer. Less number of competitors and expected launch of Phase III drug candidates will create ample growth opportunities for the global market. However, high cost of research and therapy, and stringent and time consuming regulatory process are the key barriers for the growth of the global market.

PD-1 and PD-L1 inhibitors are highly growing immunotherapies that are being used in oncology therapy area. The pipeline of PD-1 and PD-L1 inhibitors is enriched with 47 drugs and there are approximately 245 active clinical studies. There are many drugs in early stage of pipeline; thus, making PD1 and PDL1 inhibitors market very lucrative.

The information and data in the publication “Global Programmed Death-1 (PD-1) & Programmed Death Ligand-1 (PD-L1) Inhibitors Pipeline Analysis, Market Size, Share, Development, Growth and Demand Forecast to 2025” represents the research and analysis of data from various primary and secondary sources. An amalgamation of bottom-up and top-down has been used to calculate the market size. P&S Market Research analysts and consultants interacted with leading companies of the concerned domain to substantiate every value of data presented in the report. The company bases its primary research on discussions with prominent professionals and analysts in the industry, which is followed by informed and detailed, online and offline research.

Among the two mechanisms of action, the PD-1 inhibitors were estimated to contribute 97.2% to the global PD-1 and PD-L1 inhibitors market in 2016. However, the approval of Tecentriq and expected approval of durvalumab and avelumab during forecast period will significantly increase PD-L1 inhibitors revenue contribution to the global market.

Some of the key players operating in the global market include Merck & Co., Inc., Bristol-Myers Squibb Company, AstraZeneca plc and others.

【レポートの目次】

Chapter 1. Research Scope and Methodology

1.1 Market Definition

1.2 Research Scope

1.2.1 Market segmentation by drug

1.2.2 Market segmentation by mechanism of action (MoA)

1.3 Research Methodology and Sources

Chapter 2. Executive Summary

2.1 Key Findings

2.2 Research Summary

Chapter 3. Market Outlook

3.1 Introduction

3.2 Trends in the Global PD-1 & PD-L1 Inhibitors Market

3.3 Opportunities in the Global PD-1 & PD-L1 inhibitor market

3.4 Factors Driving Growth of the Market and its Impact on Market Forecast

3.5 Factors Hindering the Growth of the Market and its Impact on Market Forecast

Chapter 4. Global PD-1 & PD-L1 Inhibitors Pipeline Analysis

4.1 Overview

4.4.1 Pipeline Analysis by MOA

4.4.2 Pipeline Analysis by Molecule type

4.4.3 Pipeline Analysis by Route of Administration

4.4.4 Pipeline Analysis by Company

Chapter 5. Global PD-1 & PD-L1 Inhibitors Pipeline Analysis by Phase (2016)

5.1 Filed: Drug profiles

5.1.1 Pre-Clinical Study

5.1.2 Pre-Clinical Results

5.1.3 Clinical Trials

5.1.4 Clinical Results

5.1.5 Strategic Development

5.1.6 Designation

5.1.7 Grants

5.1.8 Patent

5.1.9 Technology

5.2 Phase III: Drug profiles

5.2.1 Pre-Clinical Study

5.2.2 Pre-Clinical Results

5.2.3 Clinical Trials

5.2.4 Clinical Results

5.2.5 Strategic Development

5.2.6 Designation

5.2.7 Grants

5.2.8 Patent

5.2.9 Technology

5.3 Phase II: Drug profiles

5.3.1 Pre-Clinical Study

5.3.2 Pre-Clinical Results

5.3.3 Clinical Trials

5.3.4 Clinical Results

5.3.5 Strategic Development

5.3.6 Designation

5.3.7 Grants

5.3.8 Patent

5.3.9 Technology

5.4 Phase I: Drug profiles

5.4.1 Pre-Clinical Study

5.4.2 Pre-Clinical Results

5.4.3 Clinical Trials

5.4.4 Clinical Results

5.4.5 Strategic Development

5.4.6 Designation

5.4.7 Grants

5.4.8 Patent

5.4.9 Technology

5.5 Pre-Clinical: Drug profiles

5.5.1 Pre-Clinical Study

5.5.2 Pre-Clinical Results

5.5.3 Strategic Development

5.5.4 Designation

5.5.5 Grants

5.5.6 Patent

5.5.7 Technology

Chapter 6 Competitive Landscape

6.1 SWOT Analysis of PD-1 and PD-L1 Inhibitors

Chapter 7 Global PD-1 & PD-L1 Inhibitors Market Size and Forecast (2015 – 2025)

7.1 Global PD-1 & PD-L1 inhibitors Market, by Drug

7.2 Global PD-1 & PD-L1 Inhibitors Market, by Mechanism of Action (MoA)

Chapter 8 Global PD-1 & PD-L1 Inhibitors Market, by Drug

8.1 Opdivo (Nivolumab) Market

8.2 Keytruda (Pembrolizumab) Market

8.3 Tecentriq (Atezolizumab) Market

8.4 Durvalumab Market

8.5 Avelumab Market

Chapter 9. Global PD-1 & PD-L1 Inhibitors Market, by Mechanism of Action (MoA)

9.1 PD-1 Inhibitor Market

9.2 PD-L1 Inhibitor Market

Chapter 10. Competitive Analysis

10.1 Porter’s Five Forces of Competitive Position Analysis

10.2 Market Share Analysis of Key Players

Chapter 11. Company Profiles and Strategic Developments

Chapter 12. Appendix

LIST OF TABLES

SPECIFIC PRIMARY AND SECONDARY SOURCES USED FOR THIS PUBLICATION

GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SNAPSHOT

ANTI-PD-1 COMBINATIONS WITH MONOCLONAL ANTIBODIES OR OTHER IMMUNO-ONCOLOGY AGENTS

ANTI-PD-L1 COMBINATIONS WITH MONOCLONAL ANTIBODIES OR OTHER IMMUNO-ONCOLOGY AGENTS

ANTI PD-1 & PD-L1 MAB COMBINATIONS WITH VACCINES

ANTI PD-1 & PD-L1 MAB COMBINED WITH GENE AND CELL THERAPIES AND OTHER NOVEL APPROACHES

DIFFERENT DRUG DESIGNATION FOR PD-1 & PD-L1 INHIBITORS

DRIVERS FOR THE MARKET: IMPACT ANALYSIS

RESTRAINTS FOR THE MARKET: IMPACT ANALYSIS

PIPELINE ANALYSIS OF PD-1 & PD-L1 INHIBITORS, BY COMPANY (2016)

DESCRIPTION OF FILED DRUG CANDIDATES

CLINICAL TRIALS OF FILED DRUG CANDIDATES

DESCRIPTION OF PHASE III DRUG CANDIDATES

CLINICAL TRIALS OF PHASE III DRUG CANDIDATES

DESCRIPTION OF PHASE II DRUG CANDIDATES

CLINICAL TRIALS OF PHASE II DRUG CANDIDATES

DESCRIPTION OF PHASE I DRUG CANDIDATES

CLINICAL TRIALS OF PHASE I DRUG CANDIDATES

DESCRIPTION OF PRE-CLINICAL DRUG CANDIDATES

SWOT ANALYSIS OF BACE INHIBITORS PIPELINE

GLOBAL PD-1 & PD-L1 INHIBITORS MARKET, BY DRUG, $M (2014 – 2016)

GLOBAL PD-1 & PD-L1 INHIBITORS MARKET, BY DRUG, $M (2017 – 2025)

GLOBAL PD-1 & PD-L1 INHIBITORS MARKET, BY MOA, $M (2014 – 2016)

GLOBAL PD-1 & PD-L1 INHIBITORS MARKET, BY MOA, $M (2017 – 2025)

GLOBAL OPDIVO MARKET, BY COUNTRY, $M (2014 – 2016)

GLOBAL OPDIVO MARKET, BY COUNTRY, $M (2017 – 2025)

COMPANIES- AT A GLANCE

LIST OF FIGURES

RESEARCH SCOPE FOR GLOBAL PD-1 & PD-L1 INHIBITORS MARKET

RESEARCH METHODOLOGY FOR GLOBAL PD-1 & PD-L1 INHIBITORS MARKET

DEACTIVATED T CELL IN PD-1 AND PD-L1

ACTIVATED T CELL IN PD-1 AND PD-L1 INHIBITORS

GLOBAL DEATHS CAUSED BY CANCER (2012)

NUMBER OF PRODUCTS UNDER DEVELOPMENT FOR PD-1 AND PD-L1 INHIBITORS (2016)

GLOBAL PD-1 AND PD-L1 INHIBITORS PIPELINE SPLIT, BY MECHANISM OF ACTION (2016)

GLOBAL PD-1 AND PD-L1 INHIBITORS PIPELINE SPLIT, BY MOLECULE TYPE (2016)

GLOBAL PD-1 AND PD-L1 INHIBITORS PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2016)

GLOBAL PD-1 & PD-L1 INHIBITORS MARKET, $M (2014 – 2025)

GLOBAL PD-1 & PD-L1 INHIBITORS MARKET, BY DRUG, $M (2014 – 2025)

GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SPLIT, BY DRUG (2016)

GLOBAL PD-1 & PD-L1 INHIBITORS MARKET, BY MOA, $M (2014 – 2025)

GLOBAL PD-1 & PD-L1 INHIBITORS MARKET SPLIT, BY MOA (2016)

GLOBAL OPDIVO MARKET, $M (2014 – 2025)

GLOBAL OPDIVO MARKET, BY COUNTRY, $M (2014 – 2025)

GLOBAL OPDIVO MARKET SPLIT, BY COUNTRY (2016)

GLOBAL KEYTRUDA MARKET, $M (2014 – 2025)

GLOBAL TECENTRIQ MARKET, $M (2014 – 2025)

GLOBAL DURVALUMAB MARKET, $M (2014 – 2025)

GLOBAL AVELUMAB MARKET, $M (2014 – 2025)

GLOBAL PD-1 INHIBITOR MARKET, $M (2014 – 2025)

GLOBAL PD-L1 INHIBITOR MARKET, $M (2014 – 2025)

PORTER’S FIVE FORCES OF COMPETITIVE POSITION ANALYSIS

MARKET SHARE ANALYSIS OF KEY PLAYERS (2016)

MARKET SHARE ANALYSIS OF KEY PLAYERS (2025)



【レポートのキーワード】

PD-1/PD-L1阻害薬

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ PD-1/PD-L1阻害薬のパイプライン分析(Global Programmed Death-1 (PD-1) & Programmed Death Ligand-1 (PD-L1) Inhibitors Pipeline Analysis, Market Size, Share, Development, Growth and Demand Forecast to 2025 - Industry Insights by Drug (Opdivo, Keytruda, Tecentriq, Durvalumab, Avelumab), by Mechanism of Action (PD-1 Inhibitor, PD-L1 Inhibitor))]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆